Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling
暂无分享,去创建一个
[1] Leslie Z. Benet,et al. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.
[2] P. Annaert,et al. INTESTINAL PERFUSION WITH MESENTERIC BLOOD SAMPLING IN WILD-TYPE AND KNOCKOUT MICE , 2009, Drug Metabolism and Disposition.
[3] J. Dressman,et al. Cytochrome P450-mediated metabolism in the human gut wall. , 2009, The Journal of pharmacy and pharmacology.
[4] P. Artursson,et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[5] P. Sinko,et al. Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats , 2008, Drug Metabolism and Disposition.
[6] C. Xia,et al. Evaluation of drug-transporter interactions using in vitro and in vivo models. , 2007, Current drug metabolism.
[7] J. Tack,et al. Parallel Monitoring of Plasma and Intraluminal Drug Concentrations in Man After Oral Administration of Fosamprenavir in the Fasted and Fed State , 2007, Pharmaceutical Research.
[8] Shufeng Zhou,et al. Role of P-glycoprotein in the Intestinal Absorption of Glabridin, an Active Flavonoid from the Root of Glycyrrhiza glabra , 2007, Drug Metabolism and Disposition.
[9] M. Wempe,et al. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[10] Patrick Augustijns,et al. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. , 2006, Journal of pharmaceutical sciences.
[11] P. Augustijns,et al. Sulfasalazine transport in in‐vitro, ex‐vivo and in‐vivo absorption models: contribution of efflux carriers and their modulation by co‐administration of synthetic nature‐identical fruit extracts , 2005, The Journal of pharmacy and pharmacology.
[12] M. Varma,et al. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. , 2005, Journal of pharmaceutical sciences.
[13] P. Augustijns,et al. HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. , 2004, Journal of pharmaceutical and biomedical analysis.
[14] P. Sinko,et al. Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.
[15] Leslie Z Benet,et al. In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model , 2003, Journal of Pharmacology and Experimental Therapeutics.
[16] P Langguth,et al. Intestinal drug efflux: formulation and food effects. , 2001, Advanced drug delivery reviews.
[17] P. Langguth,et al. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[18] Lawrence X. Yu,et al. Vitamin E-TPGS Increases Absorption Flux of an HIV Protease Inhibitor by Enhancing Its Solubility and Permeability1 , 1999, Pharmaceutical Research.
[19] P. Sinko,et al. Oral absorption of the HIV protease inhibitors: a current update. , 1999, Advanced drug delivery reviews.
[20] D. Fleisher,et al. Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration , 1999, Clinical pharmacokinetics.
[21] P. Annaert,et al. In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism , 2008 .
[22] W. Charman,et al. The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.